InterCure Ltd. (NASDAQ:INCR) Sees Large Growth in Short Interest

Posted by Dante Gardener on Feb 14th, 2026

InterCure Ltd. (NASDAQ:INCR – Get Free Report) saw a large increase in short interest in January. As of January 30th, there was short interest totaling 4,086 shares, an increase of 57.8% from the January 15th total of 2,590 shares. Based on an average trading volume of 46,481 shares, the short-interest ratio is presently 0.1 days. Based on an average trading volume of 46,481 shares, the short-interest ratio is presently 0.1 days.

InterCure Price Performance

INCR traded up $0.01 on Friday, hitting $0.90. 48,560 shares of the company’s stock were exchanged, compared to its average volume of 41,641. InterCure has a twelve month low of $0.68 and a twelve month high of $1.77. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.85 and a quick ratio of 1.09. The stock has a fifty day moving average of $1.05 and a two-hundred day moving average of $1.34.

InterCure (NASDAQ:INCR – Get Free Report) last posted its quarterly earnings results on Wednesday, October 8th. The company reported ($0.02) earnings per share (EPS) for the quarter. The firm had revenue of $19.25 million for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of InterCure in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

View Our Latest Report on InterCure

About InterCure

(Get Free Report)

InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.